1-deoxynojirimycin has been researched along with Cardiomyopathies, Primary in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Duan, W; Jiang, L; Li, XY; Liu, J; Lu, L; Shi, H; Wang, X; Yang, J; Yu, S; Zhai, M; Zhang, L; Zhu, H | 1 |
1 other study(ies) available for 1-deoxynojirimycin and Cardiomyopathies, Primary
| Article | Year |
|---|---|
1-Deoxynojirimycin attenuates septic cardiomyopathy by regulating oxidative stress, apoptosis, and inflammation via the JAK2/STAT6 signaling pathway.
Topics: 1-Deoxynojirimycin; Animals; Antiviral Agents; Apoptosis; Cardiomyopathies; Cytokines; Heart Diseases; Hypoglycemic Agents; Inflammation; Janus Kinase 2; Janus Kinases; Lipopolysaccharides; Mice; Oxidative Stress; Reactive Oxygen Species; Sepsis; Signal Transduction | 2022 |